Excelsior Correspondent
SRINAGAR, May 30: The Directorate of Health Services, Kashmir (DHSK) today directed the immediate discontinuation of a drug used in local anaesthesia due to reported adverse drug reactions.
The drug has been named as Injection Bupivacaine Hydrochloride, Batch No. AA4012B, Date of Manufacture: 03/2024, and Date of Expiry: 02/2026.
As per a communication issued in this regard, all Chief Medical Officers (CMOs) and Medical Superintendents have been directed to immediately discontinue the use of the drug batch across all healthcare institutions in the Kashmir Division.
“It has come to the notice of this Directorate that adverse post-operative reactions have been reported in association with the use of Injection Bupivacaine Hydrochloride,” the communication said.
The directive has been issued in view of patient safety concerns and as a precautionary measure.
Follow our WhatsApp channel
